Table 1 Baseline demographic and disease characteristics
Baseline characteristic | MTX | ADA | ADA + MTX |
|---|---|---|---|
(n = 202) | (n = 203) | (n = 226) | |
Age, years | 52.7 ± 13.3 | 52.0 ± 12.9 | 52.0 ± 14.1 |
Female, n (%) | 149 (73.8) | 154 (75.9) | 159 (70.4) |
Disease duration, years | 0.8 ± 0.9 | 0.7 ± 0.8 | 0.7 ± 0.8 |
Rheumatoid factor-positive, n (%) | 172 (85.6) | 172 (84.7) | 191 (84.5) |
Prior DMARD use, n (%) | 61 (30.2) | 68 (33.5) | 69 (30.5) |
Baseline corticosteroid use, n (%) | 68 (33.7) | 74 (36.5) | 81 (35.8) |
SJC (0 to 66) | 22.3 ± 12.0 | 21.6 ± 10.4 | 21.4 ± 11.5 |
TJC (0 to 68) | 32.0 ± 14.3 | 32.5 ± 13.8 | 30.5 ± 14.5 |
DAS28-CRP (0 to 10) | 6.3 ± 0.9 | 6.3 ± 0.9 | 6.3 ± 0.9 |
DAS28-CRP ≥5.1, n (%) | 183 (93.4) | 177 (88.9) | 196 (90.3) |
HAQ-DI (0 to 3) | 1.5 ± 0.7 | 1.6 ± 0.6 | 1.5 ± 0.6 |
CRP, mg/dL | 4.0 ± 4.0 | 3.8 ± 3.6 | 3.9 ± 4.1 |
mTSS (0 to 398) | 22.5 ± 22.6 | 19.0 ± 18.9 | 18.7 ± 20.7 |
JE (0 to 230)a | 14.0 ± 13.7 | 11.5 ± 11.5 | 11.4 ± 12.9 |
JSN (0 to 168) | 8.5 ± 10.9 | 7.5 ± 8.8 | 7.3 ± 9.4 |